Why Your CJC+Ipamorelin Isn't Working on Retatrutide

Your body releases growth hormone in pulses, and almost every one of those pulses happens when insulin is low, which is why the standard advice for growth hormone peptides has always been to inject on an empty stomach and wait at least two hours after a meal before you do.

The two hour window exists because that is roughly how long it takes for insulin to return to baseline after eating. Insulin and growth hormone operate like a gas pedal and a brake, and insulin is the brake. When insulin is elevated, it binds to receptors on the somatotroph cells in your anterior pituitary, the cells responsible for releasing growth hormone, and it suppresses them directly. So if you inject CJC-1295, Ipamorelin, Sermorelin, or any other growth hormone secretagogue while insulin is still elevated from a meal, you are sending a signal to a system that is actively being told to stay quiet. The peptide does its job. The pituitary does not respond. You paid for a pulse you did not get.

That is the baseline system. Now here is where retatrutide changes everything.

Retatrutide is a triple agonist, meaning it activates three receptors simultaneously: GLP-1, GIP, and glucagon. The GLP-1 component does something specific to your gastrointestinal tract, something called delayed gastric emptying, which means the rate at which food moves out of your stomach and into your small intestine is slowed significantly. This matters because insulin does not spike from the food sitting in your stomach. It spikes from nutrients being absorbed in your small intestine. Slow the transit, and you slow, extend, and shift the entire insulin curve.

Researchers measured exactly how much GLP-1 drugs slow this process. In one study on semaglutide, another GLP-1 receptor agonist, gastric half-emptying time, which is the point at which half of a meal has left your stomach, went from 118 minutes to 171 minutes. That is roughly two hours to nearly three hours. At the two hour mark specifically, there was 25.5 percent more food still sitting in the stomach compared to people not on the drug. And the gap did not close at three hours. It widened. At three hours, there was 38 percent more retained gastric contents in the GLP-1 group.

Retatrutide specifically has been shown to delay gastric emptying as well, with researchers measuring a roughly one hour delay in the time it takes for an oral dose to reach peak absorption. That effect was present at Day 30 and still present at Day 79, meaning it does not diminish as your body adjusts.

The anesthesiology community noticed this first. Standard pre-surgical fasting guidelines assume a normal stomach. But when anesthesiologists started seeing patients on GLP-1 drugs who had fasted for seven to eighteen hours and still had retained solid gastric contents on imaging, the guidelines changed. They could not trust that the stomach was empty on the usual timeline.

Now bring that back to your evening injection protocol.

You eat dinner at seven. You wait two hours. You inject at nine. By the standard rule, you are fasted. But on retatrutide, that two hour window does not represent an empty stomach or a returned-to-baseline insulin level. Food is still sitting in your stomach, still slowly passing into your small intestine, still driving a slow, extended absorption curve, and your insulin is still measurably above fasting levels. You inject your secretagogue into that hormonal environment and the pituitary suppression is still in place. The peptide fires. Nothing responds.

This is not a theoretical concern. It is the direct mechanical consequence of stacking a compound that delays gastric emptying with compounds that require low insulin to work.

The fix is straightforward. Move your growth hormone peptides to first thing in the morning, right when you wake up, before eating anything. After eight to ten hours of overnight sleep, your stomach has had enough time to empty even with retatrutide slowing the process down. Insulin is at its true fasting baseline. The somatotrophs in your pituitary are unblocked and ready to respond to the secretagogue signal. That overnight fast is the one window retatrutide cannot meaningfully compress.

One concern people raise about morning dosing is whether timing relative to sleep matters, since natural growth hormone pulses cluster around the first few hours of deep sleep. That concern is reasonable but may not be as significant as it sounds. Research comparing evening and morning injections in growth hormone deficient patients found that 24-hour IGF-1 levels were equivalent between the two timing protocols. The pituitary does not require the sleep context to respond to a secretagogue. It requires low insulin and an intact signal. Morning dosing provides both.

After you inject, eat your first meal within 30 to 60 minutes. This is not optional if you care about the downstream output. Growth hormone itself does not build tissue directly. It travels to the liver and the liver converts it into something called IGF-1, which is insulin-like growth factor 1, the compound that actually drives the anabolic effects most people are chasing. That conversion process requires insulin to be present in the liver. So you need a fasted state for the injection and an insulin signal for the conversion. Morning dosing handles both: the overnight fast gives you the empty, low-insulin window, and breakfast provides the insulin the liver needs to do its job.

The broader principle here is that when you stack compounds that each have their own metabolic effects, those effects do not stay in their own lanes. Retatrutide is slowing the movement of food through your gut. That single mechanism shifts your insulin curve, which changes the window your growth hormone peptides need to work in, which changes when you should inject them, which changes when you should eat relative to that injection. One mechanism in one system cascades into a different protocol for a completely different system.

That is not a complication. That is just pharmacology. But you have to know it is happening, or you are running a protocol optimized for a body that retatrutide has already changed.

---

References

1. Urva S, Coskun T, Loghin C, et al. 2023. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes, Obesity and Metabolism. Finding: Retatrutide at doses ≥3mg delayed acetaminophen Tmax by approximately 1 hour, with effects persisting at Day 30 and Day 79. Source
2. Jensterle M, et al. 2023. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes, Obesity and Metabolism. Finding: Gastric half-emptying time increased from 118 minutes to 171 minutes on semaglutide. At 2 hours, 25.5% more gastric contents retained vs placebo. At 3 hours, 38% more retained. Source
3. Silveira SQ, et al. 2023. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. Journal of Clinical Endocrinology \& Metabolism. Finding: GLP-1 RA patients had gastric half-emptying of 138 minutes vs 95 minutes on placebo. Patients fasting 7-18 hours still had retained solid gastric contents. Source
4. Jorgensen JO, et al. 1990. Evening versus morning injections of growth hormone in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab. Finding: 24-hour IGF-1 levels were equivalent between morning and evening injection timing. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness